Puma Biotechnology, Inc. (NASDAQ: PBYI), a notable player in the biopharmaceutical sector, has announced a conference call scheduled for February 26, 2026. The call is set to begin at 1:30 p.m. PT / 4:30 p.m. ET, following the release of the company’s financial results for the fourth quarter and full year of 2025. This event is highly anticipated by investors and analysts alike, as it will provide insights into Puma's financial performance and strategic direction.

2. How to Access the Call

To participate in the conference call, interested parties can dial 1-877-709-8150 for domestic callers or 1-201-689-8354 for international callers. Participants are advised to join the call at least 10 minutes early, informing the operator of their intent to join the “Puma Biotechnology Conference Call.” Additionally, a live webcast of the call along with presentation slides will be accessible through the Investors section of Puma's website. Following the call, a replay will be available for 90 days, allowing stakeholders to review the discussion at their convenience.

3. Puma's Commitment to Cancer Care

Puma Biotechnology is at the forefront of developing and commercializing innovative treatments aimed at improving cancer care. The company gained significant recognition with its flagship product, NERLYNX® (neratinib), which received FDA approval in 2017 for the extended adjuvant treatment of adults with early-stage HER2-overexpressed/amplified breast cancer. This therapy is particularly important for patients who have already undergone trastuzumab-based therapy.

In a significant expansion of its product offerings, NERLYNX was also approved in February 2020 in combination with capecitabine for advanced or metastatic HER2-positive breast cancer patients who have previously undergone two or more anti-HER2 regimens. The European Commission provided marketing authorization for NERLYNX in 2018, further solidifying its position in the market.

4. Recent Developments: Alisertib and Clinical Trials

In a strategic move to broaden its portfolio, Puma entered into an exclusive licensing agreement for alisertib in September 2022. This small molecule, orally administered inhibitor targets aurora kinase A and is being developed primarily for small cell lung cancer and breast cancer treatments.

The company kicked off its ALISCA™-Lung1 Phase II clinical trial in February 2024, focusing on alisertib monotherapy for extensive-stage small cell lung cancer. Additionally, the ALISCA™-Breast1 trial, initiated in November 2024, explores the combination of alisertib with endocrine therapy in patients with HER2-negative, hormone receptor-positive metastatic breast cancer. These trials reflect Puma's commitment to advancing cancer therapies and addressing unmet medical needs.

5. Looking Forward

As Puma Biotechnology prepares to unveil its financial results for 2025, stakeholders will be keenly awaiting updates on the company’s ongoing clinical trials, market performance of its products, and strategic initiatives for future growth. The upcoming conference call is expected to shed light on these critical aspects, making it an event of high interest for investors and analysts in the biopharmaceutical arena.

For those who are unable to attend the live call, a replay will be accessible on Puma's website, providing an opportunity to catch up on the insights shared during this important discussion.

Original press release